IKT
IKT clinical trials: Inhibikase Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Inhibikase Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IKT on the catalyst calendar · IKT registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jun 2029Sponsor estimate | NCT07365332An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)Inhibikase Therapeutics · Pulmonary Arterial Hypertension | IKTLead | Phase 3 | Recruiting | Locked | Locked | Locked |
| Jun 30, 2030Sponsor estimate | NCT07632898Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)Inhibikase Therapeutics · Pulmonary Arterial Hypertension (PAH) | IKTLead | Phase 3 | Not yet recruiting | Locked | Locked | Locked |
| Jun 30, 2024Actual | NCT05623774A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mgInhibikase Therapeutics · CML | IKTLead | Phase 1 | Completed | Locked | Locked | Locked |
| Jun 30, 2027Sponsor estimate | NCT06643143A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)Inhibikase Therapeutics · Pulmonary Arterial Hypertension (PAH) | IKTLead | Phase 2 | Withdrawn | Locked | Locked | Locked |
- Primary completion Jun 2029Sponsor estimatePhase 3NCT07365332An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)Inhibikase Therapeutics · Pulmonary Arterial HypertensionRecruitingIKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2030Sponsor estimatePhase 3NCT07632898Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)Inhibikase Therapeutics · Pulmonary Arterial Hypertension (PAH)Not yet recruitingIKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2024ActualPhase 1NCT05623774A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mgInhibikase Therapeutics · CMLCompletedIKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2027Sponsor estimatePhase 2NCT06643143A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)Inhibikase Therapeutics · Pulmonary Arterial Hypertension (PAH)WithdrawnIKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner